MEDP 最新10-Q变化
将 MEDP 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-23 与上一份 10-Q · 2026-04-23
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +15 | −15 | ~19 | 19 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 4 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 其他信息 | 文字有新增/删除 | +9 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-23
The effect of foreign currency adjustments on backlog was as follows: favorable foreign currency adjustments of $0.1 million for the three months ended June 30, 2026; unfavorable foreign currency adjustments of $3.6 million for the six months ended June 30, 2026; favorable foreign currency adjustmen…
Six Months Ended June 30, 2026 compared to Six Months Ended June 30, 2025
Direct service costs, excluding depreciation and amortization400,829 363,642 37,187 10.2 %
Total revenue increased by $104.0 million, to $707.3 million for the three months ended June 30, 2026, from $603.3 million for the three months ended June 30, 2025. Total revenue increased by $252.1 million, to $1,413.9 million for the six months ended June 30, 2026, from $1,161.9 million for the si…
Total direct costs increased by $82.4 million, to $505.7 million for the three months ended June 30, 2026 from $423.3 million for the three months ended June 30, 2025. Total direct costs increased by $212.5 million, to $1,016.0 million for the six months ended June 30, 2026 from $803.5 million for t…
相对上期删除的文字 · 来源:10-Q · 2026-04-23
The effect of foreign currency adjustments on backlog was as follows: unfavorable foreign currency adjustments of $3.7 million for the three months ended March 31, 2026 and favorable foreign currency adjustments of $6.9 million for the three months ended March 31, 2025.
Total revenue increased by $148.0 million, to $706.6 million for the three months ended March 31, 2026, from $558.6 million for the three months ended March 31, 2025. The increase for the three months ended March 31, 2026 was primarily driven by growth within the Metabolic, Oncology, Central Nervous…
Total direct costs increased by $130.1 million, to $510.3 million for the three months ended March 31, 2026, from $380.2 million for the three months ended March 31, 2025. The increase was primarily attributed to higher reimbursed out-of-pocket expenses and higher personnel costs to support the grow…
Selling, general and administrative expenses decreased by $10.0 million, to $47.9 million for the three months ended March 31, 2026, from $57.9 million for the three months ended March 31, 2025. The decrease was primarily attributed to a decrease in stock-based compensation expense of $11.9 million,…
based compensation expense, to support the growth in service activities of $1.5 million for the three months ended March 31, 2026, compared to the same period in the prior year.
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-07-23
ActionDateTrading ArrangementTotal Shares to be Purchased or SoldDuration/Expiration Date
The earlier of until cancelled or 180 days from the placement of the limit order
The earlier of until cancelled or 180 days from the placement of the limit order
The earlier of until cancelled or 180 days from the placement of the limit order
Intended to satisfy the affirmative defense of Rule 10b5-1(c).
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议